Berberine Ameliorates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Rats via Activation of SIRT3/AMPK/ACC Pathway

Springer Science and Business Media LLC - Tập 39 - Trang 37-43 - 2019
Yu-pei Zhang1, Yuan-jun Deng1, Kai-rui Tang1, Run-sen Chen1, Shu Liang1, Yin-ji Liang1, Li Han2, Ling Jin2, Zi-en Liang1, Yan-ning Chen1, Qin-he Yang1
1School of Traditional Chinese Medicine, Guangzhou, China
2Department of Traditional Chinese Medicine, The First Affiliated Hospital of Jinan University, Guangzhou, China

Tóm tắt

This study aimed to verify the effects of berberine (BBR) on the fat metabolism proteins involved in the sirtuin 3 (SIRT3)/adenosine 5’-monophosphate (AMP)-activated protein kinase (AMPK)/acetyl-CoA carboxylase (ACC) pathway in the liver tissues of rats with high-fat diet (HFD)-induced non-alcoholic fatty liver disease (NAFLD). Forty-eight rats were randomly divided into the normal control (NC) group, HFD group or BBR group, with 16 rats in each group. After 8 and 16 weeks of treatment, serum and liver samples were collected. Subsequently, body parameters, biochemical parameters and liver pathology were examined. The expression levels of proteins involved in the SIRT3/AMPK/ACC pathway in the liver were detected by Western blotting. After 8 and 16 weeks of a HFD, the successful establishment of rat models with different degrees of NAFLD was confirmed by hematoxylin and eosin (H&E) and Oil Red O staining. NAFLD rat models exhibited obesity and hyperlipidemia, and the protein expression levels of SIRT3, p-AMPK, p-ACC, and CPT-1A in the liver were significantly decreased compared to those in the NC group. The concurrent administration of BBR with the HFD effectively improved serum and liver lipid profiles and ameliorated liver injury. Furthermore, the protein expression levels of SIRT3, p-AMPK, p-ACC, and CPT-1A in the liver were significantly increased in the BBR group as compared with those in the HFD group. In conclusion, our data suggest that the mechanism by which BBR ameliorates HFD-induced hepatic steatosis may be related to the activation of the SIRT3/AMPK/ACC pathway in the liver.

Tài liệu tham khảo

Rinella ME. Nonalcoholic Fatty Liver Disease. JAMA, 2015,313(22):2263

Argo CK, Caldwell SH. Epidemiology and natural history of non–alcoholic steatohepatitis. Clin Liver Dis, 2009,13(4):511–531

Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol, 2013,10(11):686–690

Fan JG, Farrell GC. Epidemiology of non–alcoholic fatty liver disease in China. J Hepatol, 2009,50(1):204–210

Alisi A, Manco M, Panera N, et al. Association between type two diabetes and non–alcoholic fatty liver disease in youth. Ann Hepatol, 2009,8(Suppl 1):S44–S50

Nassir F, Ibdah JA. Role of mitochondria in nonalcoholic fatty liver disease. Int J Mol Sci, 2014,15(5):8713–8742

Osborne B, Bentley NL, Montgomery MK, et al. The role of mitochondrial sirtuins in health and disease. Free Radical Bio Med, 2016,100:164–174

Hirschey MD, Shimazu T, Goetzman E, et al. SIRT3 regulates mitochondrial fatty–acid oxidation by reversible enzyme deacetylation. Nature, 2010,464(7285):121–125

Hirschey MD, Shimazu T, Huang JY, et al. SIRT3 regulates mitochondrial protein acetylation and intermediary metabolism. Cold Spring Harb Symp Quant Biol, 2011,76:267–277

Shi T, Fan GQ, Xiao SD. SIRT3 reduces lipid accumulation via AMPK activation in human hepatic cells. J Dig Dis, 2010,11(1):55–62

Zhang SJ, Li YF, Wang GE, et al. Caffeine ameliorates high energy diet–induced hepatic steatosis: sirtuin 3 acts as a bridge in the lipid metabolism pathway. Food Funct, 2015,6(8):2578–2587

Ge Y, Zhang Y, Li R, et al. Berberine regulated Gck, G6pc, Pck1 and Srebp–1c expression and activated AMPactivated protein kinase in primary rat hepatocytes. Int J Biol Sci, 2011,7(5):673–684

Lee YS, Kim WS, Kim KH, et al. Berberine, a natural plant product, activates AMP–activated protein kinase with beneficial metabolic effects in diabetic and insulinresistant states. Diabetes, 2006,55(8):2256–2264

Yin J, Gao Z, Liu D, et al. Berberine improves glucose metabolism through induction of glycolysis. Am J Physiol Endocrinol Metab, 2008,294(1):E148–E156

Chang X, Yan H, Fei J, et al. Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high–fat diet in rats. J Lipid Res, 2010,51(9):2504–2515

Yan HM, Xia MF, Wang Y, et al. Efficacy of Berberine in Patients with Non–Alcoholic Fatty Liver Disease. PLos One, 2015,10(8):e134172

Teodoro JS, Duarte FV, Gomes AP, et al. Berberine reverts hepatic mitochondrial dysfunction in high–fat fed rats: a possible role for SirT3 activation. Mitochondrion, 2013,13(6):637–646

Gomes AP, Duarte FV, Nunes P, et al. Berberine protects against high fat diet–induced dysfunction in muscle mitochondria by inducing SIRT1–dependent mitochondrial biogenesis. Biochim Biophys Acta, 2012,1822(2):185–195

Zhao L, Cang Z, Sun H, et al. Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease. Bmc Endocr Disord, 2017,17:13

Guo T, Woo SL, Guo X, et al. Berberine Ameliorates Hepatic Steatosis and Suppresses Liver and Adipose Tissue Inflammation in Mice with Diet–induced Obesity. Sci Rep, 2016,6:22 612

Kim WS, Lee YS, Cha SH, et al. Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. Am J Physiol Endocrinol Metab, 2009,296(4):E812–E819

Sanches SC, Ramalho LN, Augusto MJ, et al. Nonalcoholic Steatohepatitis: A Search for Factual Animal Models. Biomed Res Int, 2015,2015:574832

Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology, 2010,51(2):679–689

Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science, 2011,332(6037):1519–1523

Vilar–Gomez E, Martinez–Perez Y, Calzadilla–Bertot L, et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology, 2015,149(2):367–378, e14–e15

Xie W, Gu D, Li J, et al. Effects and action mechanisms of berberine and Rhizoma coptidis on gut microbes and obesity in high–fat diet–fed C57BL/6J mice. PLos One, 2011,6(9):e24520

Chatrath H, Vuppalanchi R, Chalasani N. Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis, 2012,32(1):22–29

Hirschey MD, Shimazu T, Jing E, et al. SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome. Mol Cell, 2011,44(2):177–190

Wu T, Liu YH, Fu YC, et al. Direct evidence of sirtuin downregulation in the liver of non–alcoholic fatty liver disease patients. Ann Clin Lab Sci, 2014,44(4):410–418

Huang YY, Gusdon AM, Qu S. Nonalcoholic fatty liver disease: molecular pathways and therapeutic strategies. Lipids Health Dis, 2013,12:171

Kahn BB, Alquier T, Carling D, et al. AMP–activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab, 2005,1(1):15–25

Teodoro JS, Duarte FV, Gomes AP, et al. Berberine reverts hepatic mitochondrial dysfunction in high–fat fed rats: a possible role for SirT3 activation. Mitochondrion, 2013,13(6):637–646

Shukla S, Sharma A, Pandey VK, et al. Concurrent acetylation of FoxO1/3a and p53 due to sirtuins inhibition elicit Bim/PUMA mediated mitochondrial dysfunction and apoptosis in berberine–treated HepG2 cells. Toxicol Appl Pharmacol, 2016,291:70–83

Xu M, Xiao Y, Yin J, et al. Berberine promotes glucose consumption independently of AMP–activated protein kinase activation. PLos One, 2014,9(7):e103702

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Tập 39

37-43

Thông tin tác giả